nimorazole

Chemical data

Formula

C9H14N4O3

Molecular weight

226.23 g/mol

IUPAC name

4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine

SMILES

C1COCCN1CCN2C=NC=C2[N+](=O)[O-]

InChIKey

MDJFHRLTPRPZLY-UHFFFAOYSA-N

XLogP

-0.4

Polar surface area

76.1 Ų

H-bond donors

0

H-bond acceptors

5

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Phase 3

Molecule type

Small molecule

Indications

head and neck squamous cell carcinoma, squamous cell carcinoma, amebiasis

via ChEMBL · EBI

• Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024
• Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.Journal of translational medicine · 2023
• Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).International journal of radiation oncology, biology, physics · 2024
• (15) N NMR Hyperpolarization of Radiosensitizing Antibiotic Nimorazole by Reversible Parahydrogen Exchange in Microtesla Magnetic Fields.Angewandte Chemie (International ed. in English) · 2021
• NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2014

via PubMed

Wikidata facts

Subclass of

chemical compound

Mass

226.107

via Wikidata · CC0